

Resource Summary Report

Generated by [ASWG](#) on Aug 2, 2026

Leiden University Medical Center Flow Cytometry Core Facility

RRID:SCR_023903

Type: Tool

Proper Citation

Leiden University Medical Center Flow Cytometry Core Facility (RRID:SCR_023903)

Resource Information

URL: <https://www.lumc.nl/en/research/facilities/flow-cytometry-core-facility/>

Proper Citation: Leiden University Medical Center Flow Cytometry Core Facility (RRID:SCR_023903)

Description: Provides flow cytometers for users from the LUMC, Leiden University and external companies. Instruments include conventional and spectral analyzers, cell sorters and mass cytometers. These instruments allow analysis and sorting up to biohazard level ML-II, while one analyzer is available for ML-III material. Provides support for all aspects of cytometry, including experimental design, instrument setup, data acquisition and data analysis.

Abbreviations: LUMC FCF

Synonyms: Flow Cytometry Core Facility

Resource Type: core facility, service resource, access service resource

Keywords: USEDit, ABRF, conventional and spectral analyzers, cell sorter, mass cytometer, experimental design, data acquisition, data analysis,

Availability: Open

Resource Name: Leiden University Medical Center Flow Cytometry Core Facility

Resource ID: SCR_023903

Alternate IDs: ABRF_1819

Alternate URLs: <https://coremarketplace.org/?FacilityID=1819&citation=1>

Record Creation Time: 20230802T050218+0000

Record Last Update: 20260801T191300+0000

Ratings and Alerts

No rating or validation information has been found for Leiden University Medical Center Flow Cytometry Core Facility.

No alerts have been found for Leiden University Medical Center Flow Cytometry Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Groeneveldt C, et al. (2024) Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies. Cancer immunology research, 12(3), 334.